NCT06031779Completed
Application of Serum Bile Acid Profile in the Diagnosis of Gastric Cancer
Source: ClinicalTrials.gov · Last updated 3 Jul 2025
Brief summary (registry, in English)
In this study, the composition and level of serum bile acids in patients with gastric cancer and non-gastric cancer were analyzed by detecting the serum bile acid profile, so as to develop new serological diagnostic methods for early diagnosis and treatment of gastric cancer.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 1000 (actual)
- First submitted
- 3 Sept 2023
- Start date
- 1 May 2023
- Primary completion date
- 1 May 2024
- Lead sponsor
- Xijing Hospital of Digestive Diseases
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06031779
What you commit to
- Study type: Observational
- Participants enrolled: 1000
- From 1 May 2023 to the primary completion date, 1 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received radiotherapy or surgery previously;
Other illness
- The patients have diseases that affect bile acid metabolism, such as liver cirrhosis, gallstones or inflammatory bowel disease, Behcet's disease, etc;
- Due to other diseases, the patient took drugs affecting bile acid metabolism, such as cholestyramine, anti-inflammatory Lidan tablets, Danshu capsules, ursodeoxycholic acid, obticholic acid, Schisandrin B, tanshinone ⅡA, Yinzhihuang, etc;
- Those with poor physiopathological conditions, such as chronic kidney disease requiring long-term dialysis;
- Patients with mental illness;
Other
- Pregnant women;
- Primary tumors of other systems were diagnosed;
- Those with poor adherence or difficult to follow up.
Who the study is looking for
- Age between 18-70, both gender;
- The gastric cancer group was early gastric cancer or advanced gastric cancer diagnosed by endoscopic examination and pathological biopsy. The non-gastric cancer group included patients without gastric lesions, superficial gastritis, chronic atrophic gastritis, intestinal metaplasia or dysplasia diagnosed by gastroscopy or pathological biopsy;
- Informed consent was obtained.
Age in the registry: 18 years to 75 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xijing Hosipital of Digestive Disease Coordinator of this site? Confirm its status | Xi'an | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.